Search research articles
Contact Us
Filters
Showing results (31-40 of 99) with videos related to
Page
of 10
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 3, 2016
The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia
Bruno François, Jean Chastre, Philippe Eggiman, et al.
Pathogens & Immunity
|
March 1, 2019
HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles
Mohamed Tarek M Shata, Enass A Abdel-Hameed, Susan D Rouster, et al.
BMC Infectious Diseases
|
June 22, 2012
Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women
Jia Ji, Hai-Kui Sun, Jennifer S Smith, et al.
Infectious Diseases and Therapy
|
May 4, 2024
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials
Myron J Levin, Andrew Ustianowski, Stephane De Wit, et al.
Plos One
|
November 9, 2013
Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age
Elissa Malkin, Ram Yogev, Nazha Abughali, et al.
Nature Medicine
|
April 22, 2024
Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
Deidre Wilkins, Yuan Yuan, Yue Chang, et al.
Clinical and Vaccine Immunology : CVI
|
July 7, 2017
Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses
Judith Falloon, H Keipp Talbot, Craig Curtis, et al.
Antimicrobial Agents and Chemotherapy
|
June 22, 2016
Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893
David E Tabor, Li Yu, Hoyin Mok, et al.
Nature Medicine
|
April 24, 2023
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
Deidre Wilkins, Yuan Yuan, Yue Chang, et al.
The Journal of Infectious Diseases
|
October 24, 2007
Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine
Anna R Giuliano, Eduardo Lazcano-Ponce, Luisa Villa, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 99) with videos related to
Sort By:
Page
of 10
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 3, 2016
The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia
Bruno François, Jean Chastre, Philippe Eggiman, et al.
Pathogens & Immunity
|
March 1, 2019
HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles
Mohamed Tarek M Shata, Enass A Abdel-Hameed, Susan D Rouster, et al.
BMC Infectious Diseases
|
June 22, 2012
Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women
Jia Ji, Hai-Kui Sun, Jennifer S Smith, et al.
Infectious Diseases and Therapy
|
May 4, 2024
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials
Myron J Levin, Andrew Ustianowski, Stephane De Wit, et al.
Plos One
|
November 9, 2013
Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age
Elissa Malkin, Ram Yogev, Nazha Abughali, et al.
Nature Medicine
|
April 22, 2024
Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
Deidre Wilkins, Yuan Yuan, Yue Chang, et al.
Clinical and Vaccine Immunology : CVI
|
July 7, 2017
Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses
Judith Falloon, H Keipp Talbot, Craig Curtis, et al.
Antimicrobial Agents and Chemotherapy
|
June 22, 2016
Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893
David E Tabor, Li Yu, Hoyin Mok, et al.
Nature Medicine
|
April 24, 2023
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
Deidre Wilkins, Yuan Yuan, Yue Chang, et al.
The Journal of Infectious Diseases
|
October 24, 2007
Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine
Anna R Giuliano, Eduardo Lazcano-Ponce, Luisa Villa, et al.
Page
of 10